Holen Sie sich die Stockscreener-App
17.01
1.28%
-0.22
Handel nachbörslich:
17.22
0.21
+1.23%
Schlusskurs vom Vortag:
$17.23
Offen:
$17.65
24-Stunden-Volumen:
2.68M
Relative Volume:
0.84
Marktkapitalisierung:
$12.66B
Einnahmen:
$220.00K
Nettoeinkommen (Verlust:
$-746.08M
KGV:
-16.89
EPS:
-1.0074
Netto-Cashflow:
$-211.81M
1W Leistung:
-5.18%
1M Leistung:
+0.35%
6M Leistung:
-14.31%
1J Leistung:
-8.40%
1-Tages-Spanne:
$16.99
$17.85
1-Wochen-Bereich:
$16.87
$18.22
52-Wochen-Spanne:
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
Firmenname
Summit Therapeutics Inc
Sektor
Branche
Telefon
305-203-2034
Adresse
601 BRICKELL KEY DRIVE, MIAMI
Vergleichen Sie SMMT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.01 | 12.83B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
449.52 | 115.43B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.79 | 78.44B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
862.05 | 52.42B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.10 | 51.68B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.46 | 42.80B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-18 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-09-17 | Eingeleitet | Barclays | Underweight |
| 2025-09-04 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Neutral |
| 2025-07-01 | Eingeleitet | UBS | Buy |
| 2025-06-11 | Eingeleitet | Leerink Partners | Underperform |
| 2025-03-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-03-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-03-12 | Eingeleitet | Evercore ISI | Outperform |
| 2025-02-28 | Eingeleitet | Goldman | Buy |
| 2025-01-08 | Eingeleitet | Truist | Buy |
| 2024-12-11 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-06 | Eingeleitet | Jefferies | Buy |
| 2024-11-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-09-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-08-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-07 | Eingeleitet | Citigroup | Buy |
| 2024-03-26 | Eingeleitet | Stifel | Buy |
| 2018-06-28 | Herabstufung | Janney | Buy → Neutral |
| 2018-05-02 | Eingeleitet | Janney | Buy |
| 2018-04-12 | Bestätigt | Needham | Buy |
| 2018-02-13 | Eingeleitet | BTIG Research | Buy |
| 2018-01-04 | Eingeleitet | SunTrust | Buy |
| 2017-12-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-16 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-10-05 | Bestätigt | Needham | Buy |
| 2016-09-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-03-30 | Eingeleitet | Needham | Buy |
| 2015-03-30 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Summit Therapeutics Inc Aktie (SMMT) Neueste Nachrichten
Barclays Upgrades SMMT, Raises Price Target to $18 | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Barclays to Equal Weight Rating - MarketBeat
Summit Therapeutics stock rating upgraded by Barclays on BLA timeline - Investing.com UK
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.4%Here's Why - MarketBeat
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - The Motley Fool
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Summit Therapeutics (NASDAQ:SMMT) Trading 9.2% HigherShould You Buy? - MarketBeat
Can Summit Therapeutics Inc. stock maintain operating marginsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Summit Therapeutics Earnings Notes - Trefis
Don't Buy Summit Therapeutics Until This Big Thing Happen - Nasdaq
Widening Q3 Losses and Insider Buying Might Change The Case For Investing In Summit Therapeutics (SMMT) - Yahoo Finance
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
SMMT: Four positive phase 3 trials and accelerated timelines position the pipeline for NSCLC market leadership - TradingView
XTX Topco Ltd Makes New $925,000 Investment in Summit Therapeutics PLC $SMMT - MarketBeat
2 Monster Stocks in the Making to Buy and Hold - The Globe and Mail
Summit Therapeutics: InvestingPro’s Fair Value model predicted 37% downside By Investing.com - Investing.com Nigeria
Summit Therapeutics (SMMT) Stock Analysis Report | Financials & Insights - Benzinga
33,096 Shares in Summit Therapeutics PLC $SMMT Acquired by Inceptionr LLC - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
WE Convention 2025: Dr. Maky Zanganeh, Co-CEO and President, Summit Therapeutics - Entrepreneur
January 2026 Options Now Available For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics Inc. (SMMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cynosure Group LLC Buys Shares of 18,609 Summit Therapeutics PLC $SMMT - MarketBeat
Biotech Alert: Searches spiking for these stocks today - TipRanks
40,169 Shares in Summit Therapeutics PLC $SMMT Acquired by Neo Ivy Capital Management - MarketBeat
(SMMT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Summit C-Suite Risks Success, Akeso Wins Either Way (OTCMKTS:AKESF) - Seeking Alpha
Jefferies Cuts Summit Therapeutics (SMMT) Price Target, Keeps Buy Rating - MSN
ProShare Advisors LLC Sells 25,455 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Is Summit Therapeutics Inc. building a consolidation baseMarket Rally & Weekly Top Stock Performers List - newser.com
What MACD and RSI say about Summit Therapeutics Inc.Gap Up & Weekly Chart Analysis and Trade Guides - newser.com
Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying (NASDAQ:SMMT) - Seeking Alpha
Summit Therapeutics (NASDAQ:SMMT) Now Covered by Wolfe Research - MarketBeat
Finanzdaten der Summit Therapeutics Inc-Aktie (SMMT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.18%
0.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):